Nature Cancer

Scope & Guideline

Advancing the Frontier of Cancer Research

Introduction

Welcome to the Nature Cancer information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Nature Cancer, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN-
PublisherNATURE PORTFOLIO
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationNAT CANCER / Nat. Cancer
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressHEIDELBERGER PLATZ 3, BERLIN 14197, GERMANY

Aims and Scopes

Nature Cancer focuses on cutting-edge research that addresses the complexities of cancer biology, treatment, and patient outcomes. The journal encompasses a broad range of topics with a commitment to improving cancer care through innovation and interdisciplinary approaches.
  1. Cancer Immunotherapy:
    Research on various immunotherapy strategies, including CAR T cells, immune checkpoint inhibitors, and bispecific antibodies, aimed at enhancing the immune system's ability to fight cancer.
  2. Tumor Microenvironment:
    Studies examining the interactions between tumor cells and their surrounding microenvironment, including the role of immune cells, fibroblasts, and extracellular matrix in tumor progression and therapy resistance.
  3. Genomics and Precision Medicine:
    Exploration of genomic alterations in cancer, including the identification of actionable mutations and the development of personalized therapeutic strategies based on genetic and molecular profiling.
  4. Metabolism and Cancer:
    Investigations into the metabolic vulnerabilities of cancer cells and how metabolic pathways can be targeted to improve treatment efficacy and patient outcomes.
  5. Clinical Trials and Translational Research:
    Reports on clinical trial findings, including novel therapeutic agents and combinations, as well as studies that bridge laboratory findings with clinical applications.
  6. Artificial Intelligence in Cancer Research:
    Utilization of AI and machine learning techniques to analyze large datasets, predict treatment responses, and improve diagnostic accuracy in oncology.
Nature Cancer is at the forefront of emerging trends in cancer research, reflecting the dynamic nature of the field. Recent publications highlight several key themes that are gaining traction among researchers.
  1. Combination Immunotherapy Strategies:
    There is a growing emphasis on combining different immunotherapeutic approaches, such as checkpoint inhibitors with CAR T-cell therapy or targeted agents, to enhance antitumor responses and address resistance.
  2. Single-Cell and Multi-Omics Approaches:
    Research utilizing single-cell sequencing and multi-omics analyses is on the rise, providing deeper insights into tumor heterogeneity, immune microenvironments, and the intricacies of treatment responses.
  3. Targeting the Tumor Microenvironment:
    Increasing attention is being given to strategies that modify the tumor microenvironment, including targeting stromal cells and immune suppressive pathways to improve therapeutic outcomes.
  4. Metabolic Reprogramming in Cancer:
    Research exploring the metabolic adaptations of cancer cells and the potential to exploit these vulnerabilities through targeted metabolic therapies is gaining momentum.
  5. Real-World Data and AI in Oncology:
    The integration of real-world data and artificial intelligence in cancer research is trending, focusing on improving patient stratification, predicting treatment responses, and personalizing therapy.

Declining or Waning

While Nature Cancer continues to evolve, certain research themes have seen a decline in prevalence over recent years. This shift may reflect changes in scientific focus, technological advancements, or emerging areas of interest.
  1. Traditional Chemotherapy Approaches:
    Research focusing solely on conventional chemotherapy strategies appears to be waning, as the field increasingly prioritizes targeted therapies and immunotherapeutic approaches that offer more personalized treatment options.
  2. Basic Cancer Biology without Clinical Application:
    Studies that emphasize basic biological mechanisms of cancer without clear translational implications have decreased, as there is a stronger emphasis on research that has direct relevance to patient care and therapeutic development.
  3. Single-Agent Targeted Therapies:
    The focus on single-agent targeted therapies is declining in favor of combination therapies that leverage multiple mechanisms of action to overcome resistance and enhance efficacy.

Similar Journals

NEOPLASIA

Fostering collaboration to combat cancer's challenges.
Publisher: ELSEVIER SCIENCE INCISSN: 1476-5586Frequency: 12 issues/year

NEOPLASIA is an esteemed open-access journal dedicated to advancing the field of oncology, published by Elsevier Science Inc. since 1999. With an impressive impact factor and recognition as a Q1 journal in Cancer Research for 2023, it holds a significant position within the scientific community, specifically ranking in the 74th percentile globally in the categories of Biochemistry, Genetics, and Molecular Biology. NEOPLASIA seeks to provide a comprehensive platform for innovative research, covering a wide array of topics in cancer biology, treatment methodologies, and therapeutic advancements. Researchers, professionals, and students are encouraged to utilize this resource, which is easily accessible to foster collaboration and stimulate progress in cancer research. As it converges its efforts towards the future of oncology, this journal is poised to remain at the forefront of transformative discoveries that shape our understanding and treatment of cancer.

Cancer Immunology Research

Driving Progress in Cancer Treatment through Immunology
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2326-6066Frequency: 12 issues/year

Cancer Immunology Research is a leading journal dedicated to the rapidly evolving field of cancer immunology, published by the American Association for Cancer Research. Established in 2013, this prestigious journal has quickly made a significant impact in its domain, achieving a 2023 Q1 ranking in both Cancer Research and Immunology. With an impressive Scopus rank of 24 out of 230 in cancer research and 28 out of 236 in immunology, it occupies a valuable position for researchers, professionals, and students engaged in cutting-edge cancer studies. Although it does not offer open access, the journal is committed to disseminating high-quality, peer-reviewed research that advances our understanding of the immune system’s role in cancer. The journal's objectives include fostering innovative studies, enhancing collaboration across disciplines, and promoting the translation of research findings into clinical applications, making it a vital resource for anyone invested in cancer therapy and immunological research.

Molecular & Cellular Oncology

Exploring the cellular mechanisms of oncogenesis.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Elevating the standards of cancer research and treatment.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

NATURE REVIEWS CANCER

Navigating the Complexities of Cancer Science
Publisher: NATURE PORTFOLIOISSN: 1474-175XFrequency: 12 issues/year

NATURE REVIEWS CANCER, a premier journal published by NATURE PORTFOLIO, stands as a cornerstone in the field of oncology, focusing on delivering high-quality, comprehensive reviews that shape our understanding of cancer biology, prevention, and treatment. With an impressive impact in the academic community, it ranks Q1 in both Cancer Research and Oncology categories as of 2023, further denoted by a remarkable Scopus ranking as the top journal in Cancer Research and second in Oncology. This ensures that published articles not only set the standard for scientific excellence but also drive significant advancements in cancer research methodologies and practices. The journal's targeted audience, including researchers, practitioners, and students, will greatly benefit from its insightful analyses and interdisciplinary approach. While it operates under a traditional subscription model, the rich content and vast expertise presented in its articles foster a global dialogue on cancer-related issues, making it an essential resource for anyone dedicated to the advancement of cancer science.

CANCER IMMUNOLOGY IMMUNOTHERAPY

Fostering Breakthroughs in Cancer Treatment Strategies
Publisher: SPRINGERISSN: 0340-7004Frequency: 12 issues/year

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Oncologie

Elevating oncology research to new heights.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

CANCER GENE THERAPY

Advancing the Frontier of Cancer Treatment
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Cancer & Metabolism

Innovating Therapeutic Strategies at the Metabolic Frontier
Publisher: BMCISSN: Frequency: 1 issue/year

Cancer & Metabolism is a distinguished open-access journal published by BMC, dedicated to advancing the understanding of the complex interactions between cancer biology and metabolic processes. Since its inception in 2013, it has provided a platform for researchers, clinicians, and students to disseminate groundbreaking research and innovative findings within the fields of oncology and metabolism. The journal, identified by its E-ISSN 2049-3002, is recognized for contributing valuable insights into metabolic alterations that influence cancer progression, treatment responses, and overall patient outcomes. With a firm commitment to open access, Cancer & Metabolism ensures that research is freely available to the global scientific community, fostering collaboration and accelerating discoveries that can lead to improved therapeutic strategies. As a vital resource in cancer research, this journal appeals to a broad audience, including researchers looking to share their latest findings, professionals seeking to stay informed on cutting-edge developments, and students eager to delve into the relationship between metabolism and cancer.

Journal of the National Cancer Center

Elevating the Standard of Cancer Research and Treatment.
Publisher: ELSEVIERISSN: 2667-0054Frequency: 4 issues/year

Journal of the National Cancer Center, published by Elsevier, serves as a pivotal platform in the fields of Cancer Research, Hematology, and Oncology. With an ISSN of 2667-0054, this esteemed journal is recognized for its exceptional quality, achieving a Q1 ranking in all categories as of 2023. Its impressive Scopus rankings place it among the top journals in its field, notably holding rank #11 in Medicine - Hematology and rank #36 in Medicine - Oncology. Addressed from Amsterdam, Netherlands, the journal aims to disseminate cutting-edge research and innovative findings that advance the understanding and treatment of cancer, bridging gaps between laboratory discoveries and clinical applications. Although it follows a subscription model, the journal's commitment to accessibility ensures that valuable knowledge reaches healthcare professionals and researchers globally. By fostering collaboration and facilitating knowledge exchange, the Journal of the National Cancer Center is indispensable for those dedicated to combating cancer and enhancing patient care.